ChemPass Kft
ChemPass Kft is a Budapest-based AI-assisted drug discovery company offering the AID Platform, SYNSPACE rule-based molecular design tools, and lead identification/optimization services to pharmaceutical, biotechnology, and academic clients via direct sales and regional distributors.
- Company typePrivate
- Founded2016
- HeadquartersBudapest, Hungary
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What ChemPass Kft does
ChemPass Kft is a Budapest, Hungary-headquartered AI-assisted drug discovery company that develops software and services for the design of novel small organic molecules and scaffolds. The company's product architecture is a platform-plus-modules model: the AID (AI-Assisted Discovery) Platform targets lead identification and optimization for therapeutic field targets, while SYNSPACE applies rule-based AI to forward reaction-based molecular design for library design, scaffold hopping, side-chain optimization, and retrosynthesis. Supporting modules include a Universal Fragment Library platform for fragment-based drug discovery, a Virtual Chemoproteomics platform, giga-scale virtual screening, macrocyclic and kinase selectivity lead-optimization platforms, and supplementary software tools (PoseValidator for docking-pose validation and CovMap for molecular library coverage mapping).
The firm operates three revenue streams: (1) drug discovery services — including in-silico lead ID/optimization and CRO management for chemistry and biology work, delivered as professional services; (2) software licensing of SYNSPACE, PoseValidator, and CovMap; and (3) recurring technology platform access. Pricing is quote-based, contracted on a multi-year basis, and risk-sharing milestone-driven structures are offered. ChemPass serves pharmaceutical companies, biotechnology firms, and research institutions, distributing software both directly (including via a public SYNSPACE API) and through regional channel partners — Advent Informatics in India and Cloud Scientific in China. Named collaborators include AstraZeneca, Novartis, and the Keserű academic group, evidenced by a 2025 co-authored review in Nature Reviews Drug Discovery. The company was founded in 2016, has 1-10 employees, and is privately held.
ChemPass Kft firmographics
Firmographics- Name
- ChemPass Kft
- Legal name
- ChemPass Kft
- Website
- https://chempassltd.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ChemPass Kft is a Budapest-based AI-assisted drug discovery company offering the AID Platform, SYNSPACE rule-based molecular design tools, and lead identification/optimization services to pharmaceutical, biotechnology, and academic clients via direct sales and regional distributors.
- Ownership category
- akta.pro rank
ChemPass Kft industry classification
Industry- Product category
- AI-Assisted Drug Discovery Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where ChemPass Kft is headquartered
LocationHeadquarters
- HQ city
- Budapest
- HQ country
- Hungary
- HQ region
- Europe
Offices1 record
Markets served
ChemPass Kft business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Discovery Services: In-silico drug discovery services including lead identification and optimization, managed chemistry and biology CRO services for pharmaceutical and biotech partners
- Software Licensing: Licensing of proprietary software tools including SYNSPACE, PoseValidator, and CovMap. Risk-sharing milestone-driven business models are possible.
- Technology Platform Access: Access to AI-assisted discovery platform and specialized screening platforms
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on project scope |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
ChemPass Kft product offering
Product offeringCore offering
ChemPass develops and licenses an AI-assisted discovery (AID) platform and related software (SYNSPACE, PoseValidator, CovMap) that enable lead identification and lead optimization for small-molecule drug discovery. The company also delivers project-based in-silico drug discovery services, including fragment-based drug design, virtual screening, virtual chemoproteomics, lead hopping, and macrocyclic/kinase selectivity optimization, and manages chemistry and biology CROs on behalf of pharmaceutical and biotechnology partners.
Product overview
ChemPass offers a platform-plus-modules architecture combining AI-assisted discovery tools with specialized drug discovery services. The core AID Platform delivers patentable leads and drug candidates, while SYNSPACE provides rule-based AI for synthesis design and optimization. Supporting lead identification services include Universal Fragment Library, Virtual Chemoproteomics, Giga-scale Virtual Screening, and Lead Hopping. Lead optimization services encompass Macrocyclic and Kinase Selectivity platforms. Additional software tools include PoseValidator and CovMap for molecular analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- AID Platform (AI-Assisted Discovery Platform) AI-assisted discovery platform that generates patentable leads and drug candidates for therapeutic field targets, supporting lead identification and optimization workflows for pharmaceutical and biotech clients.
- SYNSPACE Versatile molecular design platform using rule-based AI for forward reaction-based design, supporting library design, scaffold hopping, side-chain optimization, and retrosynthesis, available via GUI or API.
- PoseValidator Software tool for validating molecular docking poses in drug discovery projects.
- CovMap Coverage mapping tool for analyzing molecular interaction landscapes and chemical library coverage in drug discovery.
- Universal Fragment Library Platform Fragment-based drug discovery (FBDD) platform for identifying lead compounds through fragment screening.
- Virtual Chemoproteomics Platform In-silico chemoproteomics platform for target identification and profiling.
- Giga-scale Virtual Screening Large-scale virtual screening capability for rapid identification of active compounds from massive compound libraries.
- Lead Hopping Service for discovering novel chemical scaffolds while maintaining biological activity, enabling patentable lead generation.
- Macrocyclic Platform Specialized platform for designing and optimizing macrocyclic compounds for drug discovery.
- Kinase Selectivity Platform Platform for assessing and optimizing kinase selectivity profiles during lead optimization.
Quantifiable outcome
- Patentable leads and candidates for therapeutic field targets
- +2 more outcomes
Companies that use ChemPass Kft
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
ChemPass Kft technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature10 records
ChemPass Kft partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- AstraZenecacoreCollaborative review published in Nature Reviews Drug Discovery (2025) on the changing landscape of medicinal chemistry, along with Keserű group and Novartis.
- NovartiscoreCollaborative review published in Nature Reviews Drug Discovery (2025) on the changing landscape of medicinal chemistry, along with AstraZeneca and Keserű group.
- Advent Informatics Pvt. Ltd.minorRegional distributor in Pune, India focusing on providing ChemPass software to researchers and students in cheminformatics, molecular modelling, medicinal chemistry, and related fields.
- Cloud ScientificminorRegional distributor in China specialized in serving the life sciences community with integrated scientific software solutions, including ChemPass drug design products.
- Keserű GroupcoreAcademic research collaboration on medicinal chemistry review published in Nature Reviews Drug Discovery with AstraZeneca and Novartis.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
ChemPass Kft competitors and assessment
Company assessmentDirect peers
- Molecular Discovery:
- Schrödinger: Schrödinger provides physics-based and AI/ML computational chemistry platforms for small molecule lead ID and lead optimization, plus collaborative drug discovery services. It is the most direct public-market comparable to ChemPass's combination of CADD software (LiveDesign), virtual screening, FBDD support, and co-discovery engagements with pharma.
- Insilico Medicine: Insilico Medicine operates an end-to-end AI drug discovery platform covering target ID, hit discovery, and lead optimization for small molecules, and runs a robotics-driven CRO. Overlap with ChemPass spans AI-enabled hit/lead generation, generative chemistry, and pharma partnerships, though Insilico operates at much larger scale.
- Iambic Therapeutics: Iambic (formerly Entasis) builds AI models for small molecule design and prediction, including its NeuralPLexer and Enchant platforms for lead discovery and ADMET. It is comparable to ChemPass in applying novel AI/ML architectures to small molecule discovery and in pursuing pharma collaborations, with similar emphasis on speed and computational scale.
- Atomwise: Atomwise runs AtomNet, a deep learning virtual screening platform used for small molecule hit identification, and partners with pharma on lead discovery. The business model and use cases (AI virtual screening, structure-based discovery, pharma collaborations) closely mirror ChemPass's giga-scale virtual screening and lead ID services.
- XtalPi: XtalPi combines AI, quantum physics, and robotic automation to deliver small molecule drug discovery and crystal structure prediction. Its lead ID/optimization services and platform-based engagement model parallel ChemPass's AI-assisted discovery offering, although XtalPi operates at substantially greater scale and capitalization.
- OpenEye Scientific (Cadence Molecular Sciences): OpenEye/Cadence sells cheminformatics, molecular modeling, and CADD software (e.g., OMEGA, FRED, ROCS) widely used in pharma for virtual screening and lead optimization. Comparable to ChemPass's software tools (SYNSPACE, PoseValidator, CovMap) and its strategy of licensing cheminformatics platforms alongside services.
- Cresset: Cresset provides ligand-based CADD software (Flare, Spark) and discovery services for lead ID and lead optimization. Closely comparable to ChemPass in offering both cheminformatics tools (similar in role to SYNSPACE/CovMap) and collaborative discovery services to pharma and biotech.
Broad incumbents
- Recursion Pharmaceuticals: Recursion is a clinical-stage AI-driven biotech using image-based phenomics, ML, and automation to discover small molecule therapeutics. While broader in scope than ChemPass and biased toward phenotypic/omics data, it competes for the same pharma partnership dollars and overlaps in AI-enabled lead discovery.
Market position
Strengths4 records
Competitive moat4 records
Customer concentration
ChemPass Kft social profiles
Digital presenceChemPass Kft financial estimates
Financial estimateRevenue estimate
Valuation estimate
ChemPass Kft leadership team
Management profileNumber of profiles
Profiles2 records
ChemPass Kft funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ChemPass Kft M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ChemPass Kft
What does ChemPass Kft do?
ChemPass develops and licenses an AI-assisted discovery (AID) platform and related software (SYNSPACE, PoseValidator, CovMap) that enable lead identification and lead optimization for small-molecule drug discovery. The company also delivers project-based in-silico drug discovery services, including fragment-based drug design, virtual screening, virtual chemoproteomics, lead hopping, and macrocyclic/kinase selectivity optimization, and manages chemistry and biology CROs on behalf of pharmaceutical and biotechnology partners.
Is ChemPass Kft a public or private company?
ChemPass Kft is a private company. It is classified as venture growth investor backed and is currently operating.
When was ChemPass Kft founded?
ChemPass Kft was founded in 2016. It employs 1 to 10 people.
Where is ChemPass Kft based?
ChemPass Kft is headquartered in Budapest, Hungary, in the Europe region.
How does ChemPass Kft make money?
Three revenue lines are on record. Drug Discovery Services are the primary driver. The others are software Licensing and technology Platform Access.
Who are ChemPass Kft's main competitors?
Direct peers on record are Molecular Discovery, Schrödinger, Insilico Medicine, Iambic Therapeutics, Atomwise, XtalPi, OpenEye Scientific (Cadence Molecular Sciences) and Cresset. Recursion Pharmaceuticals is listed as a broad incumbent.
Does ChemPass Kft have an API?
Yes. SYNSPACE offers a public API for library design and lead optimization ideation tasks including scaffold hopping, side-chain optimization, and retrosynthesis.
What industry is ChemPass Kft in?
ChemPass Kft's product category is AI-Assisted Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 5417 and its SIC code is 8731.